Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide

In a mouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor β1,2,3 (TGFβ1,2,3)-targeting antibody achieved superior antineoplastic effects. This novel paradigm of synergistic chemoimmunotherapy promises to improve the clinical outcome of cancer patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Wakefield, Lalage M, Oppenheim, Joost J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063140/
https://www.ncbi.nlm.nih.gov/pubmed/25050195
http://dx.doi.org/10.4161/onci.28247
_version_ 1782321753615237120
author Chen, Xin
Wakefield, Lalage M
Oppenheim, Joost J
author_facet Chen, Xin
Wakefield, Lalage M
Oppenheim, Joost J
author_sort Chen, Xin
collection PubMed
description In a mouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor β1,2,3 (TGFβ1,2,3)-targeting antibody achieved superior antineoplastic effects. This novel paradigm of synergistic chemoimmunotherapy promises to improve the clinical outcome of cancer patients with micrometastases, and thus deserves further investigation.
format Online
Article
Text
id pubmed-4063140
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40631402015-04-16 Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide Chen, Xin Wakefield, Lalage M Oppenheim, Joost J Oncoimmunology Author's View In a mouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor β1,2,3 (TGFβ1,2,3)-targeting antibody achieved superior antineoplastic effects. This novel paradigm of synergistic chemoimmunotherapy promises to improve the clinical outcome of cancer patients with micrometastases, and thus deserves further investigation. Landes Bioscience 2014-04-16 /pmc/articles/PMC4063140/ /pubmed/25050195 http://dx.doi.org/10.4161/onci.28247 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Chen, Xin
Wakefield, Lalage M
Oppenheim, Joost J
Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
title Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
title_full Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
title_fullStr Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
title_full_unstemmed Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
title_short Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
title_sort synergistic antitumor effects of a tgfβ inhibitor and cyclophosphamide
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063140/
https://www.ncbi.nlm.nih.gov/pubmed/25050195
http://dx.doi.org/10.4161/onci.28247
work_keys_str_mv AT chenxin synergisticantitumoreffectsofatgfbinhibitorandcyclophosphamide
AT wakefieldlalagem synergisticantitumoreffectsofatgfbinhibitorandcyclophosphamide
AT oppenheimjoostj synergisticantitumoreffectsofatgfbinhibitorandcyclophosphamide

Ejemplares similares